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Immunotherapy and target therapy are providing compelling proofs of clinical success in malignant 
melanoma, strengthening their role as additional options in the comprehensive treatment of melanoma 
patients. In particular, immunomodulating monoclonal antibodies (mAb) that block specific immune 
checkpoints and BRAF kinase inhibitors have been demonstrated to improve significantly the over-
all survival (OS) of metastatic melanoma patients [1,2]. More interestingly, results from pre-clinical 
studies and ongoing clinical trials suggest that these agents can also have a strong clinical impact in 
additional human malignancies beyond melanoma [3], either in combination with each other, or with 
immunotherapeutic or chemotherapeutic agents [4]. However, the swift clinical translation of emerg-
ing evidences on new therapeutic strategies and agents from the laboratory to the clinical setting is 
generally long-winded, raising new and specific procedural, ethical, and legal challenges that cannot 
be easily faced by single Institutions. Thus, to facilitate the clinical application of promising pre-clinical 
evidences generated by non-profit entities, shared efforts and interactions among different profession-
als are mandatory. To pursue this common goal, different national networks focusing on immuno-
biotherapy of cancer are being established in Europe. In this broad context, to fulfill the needs of the 
Italian scientific community, the NIBIT (acronym for the Network Italiano per la Bioterapia dei Tumori 
– Italian Network for Tumor Biotherapy) was established in 2004, and was formally given legal status as 
a non-profit association in 2006. As of today, the NIBIT accounts for more than 150 official members 
from over 40 Italian Academic, Regulatory and Industrial groups/bodies nationwide.
As per its Statute, the activities of the NIBIT (available at http://www.nibit.org; temporarily at http://
www.sienaweb.it/nibit) aim to:
 • Promote and foster scientific and operative interactions among professionals belonging to Aca-
demia, Biotech/Pharmaceutical Industry, Regulatory Bodies;
 • Set-up initiatives to inform patients on cancer bioimmunotherapy and available ongoing clinical 
trials;
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 • Train physicians about potentials and limitations of cancer bio-immunotherapy, and on available 
clinical trials;
 • Develop innovative, multi-center clinical studies of cancer bio-immunotherapy at national level.
These objectives are well identified by the NIBIT logo: 4 intermingled pieces of a puzzle (interaction, 
training, information and research) of different colors (Figure 1).
The NIBIT held its scientific annual meeting at the Certosa di Pontignano, a Tuscan monastery built by 
the Chartusian Order in 1343 that is located in the beautiful Chianti’s landscape. The annual meeting 
allows to present the most recent pre-clinical results obtained by the NIBIT groups as well as the clini-
cal activities of the Network in the context of a high level international framework. A scientific report 
is generated after the meeting and it is hosted by Cancer Immunology Immunotherapy, a peer reviewed 
international journal focused on basic, translational, and clinical cancer immunology and immuno-
therapy, that starting from 2013 is the official scientific Journal of the NIBIT. Since 2013 the annual 
NIBIT meeting is organized within the framework of the international meeting “Cancer Bio-Immuno-
therapy in Siena” in which world-acknowledged scientists join the Faculty of the NIBIT (http://www.
sienameeting-nibit.org). To promote the scientific activities of young researchers, three NIBIT prizes 
are awarded yearly for the best basic, translational and clinical contributions. To contribute to promote 
the knowledge on the results and potentials of cancer immunotherapy among the larger clinical and 
scientific community, as well as to non-dedicated health professionals, members of the NIBIT held four 
yearly itinerating courses in different Italian locations.
The courses are designed to allow time for extensive discussion between speakers and participants. In 
2014, the NIBIT will also organize in Siena the First National Master in Immuno-Oncology, aimed to 
provide a limited number of attendees with an in depth, practical experience in the clinics of cancer 
immunotherapy.
In order to better fulfill its mission on a world-wide basis, the NIBIT is member of the World Immu-
notherapy Council (http://www.sitcancer.org/about-sitc/initiatives/wic), an international forum that 
groups national organizations to facilitate high-level scientific collaborations in cancer immunology 
and immunotherapy.
Figure 1. NIBIT (upper) and NIBIT Foundation (below) logo
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Most recently the NIBIT has also designed and conducted its first clinical trial entitled: “A Phase II 
Study of the Combination of Ipilimumab and Fotemustine in Patients with Unresectable Locally Ad-
vanced or Metastatic Malignant Melanoma”. This study has involved 8 Italian Institutions with the pri-
mary objective to investigate the efficacy of the combination of the anti-CTLA-4 mAb ipilimumab and 
fotemustine in patients with unresectable locally advanced or metastatic melanoma with or without as-
ymptomatic brain metastases. The initial results of the study have been presented at major international 
meetings and have been published in The Lancet Oncology in 2012 [4]. The comprehensive success of 
this clinical study represents a great achievement for the NIBIT and shows the potential of Academic 
networks to generate high-level scientific research that overcomes the hurdles that new modalities of 
cancer bio-immunotherapy face.
In spite of the successes that cancer immuno-biotherapy is achieving, much remains to be gained in the 
identification of the fine immunologic mechanism(s) activated in treated patients, as well as on predic-
tive and prognostic biomarkers that will allow the selection of the best candidates to this therapeutic 
strategy (Ref 7). The latter represents an area of very active and competitive research; thus, an immune 
monitoring platform was established and developed by several groups that participated to the NIBIT-
M1 study. To further implement these ex-vivo activities, the first NIBIT laboratory has been established 
in 2013 to set-up and to perform translational studies foreseen in clinical trials supported or sponsored 
by the NIBIT.
In the aim to best focus the comprehensive activities connected with the development and conduction 
of non-profit clinical trials, the NIBIT Board of Directors and its Assembly, have approved the estab-
lishment of the NIBIT Foundation (http://www.fondazionenibit.org) in 2012 (Figure 1). Main objec-
tives of the NIBIT Foundation are to:
 • Develop, design and conduct clinical Phase I to IV studies;
 • Participate in projects aimed at the development of new drugs and new regimens for cancer treat-
ment;
 • Coordinate and/or participate in multicenter national and international clinical trials;
 • Promote and/or implement scientific initiatives, such as conferences, meetings, seminars, courses, 
publications;
 • Support research projects, including basic and translational programs.
On these premises, the NIBIT Foundation is presently sponsor of the NIBIT-M2 study “A randomized, 
Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients 
with Metastatic Melanoma with brain metastasis” and is working on setting up additional high-level 
clinical programs. As per the NIBIT, the clinical activities of the NIBIT Foundation aim to further 
Figure 2. The dates for the next NIBIT meeting
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strengthen operative links within the larger Italian research community, but also with international 
groups and Institutions focusing on cancer bio-immunotherapy.
Together with the NIBIT Board of Directors, we look forward to seeing you in Siena on October 9-11, 
2014 to enjoy the next NIBIT Meeting (Figure 2) and the superb beauty of Siena and of the Tuscan 
landscapes.
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